Company / Revenue
Sarepta Therapeutics Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$2.2B
FY2025
5-year range
$540.1M / $2.2B
FY2021-FY2025
Trend
+15.6%
vs FY2024
Sector context
#31 of 155
Health Care
What the data says
Sarepta Therapeutics's revenue of $2.2B is higher than 80% of companies in the Health Care sector (FY2025). Revenue has increased for 3 consecutive years, from $540M in FY2022 to $2.2B in FY2025.
Based on SEC 10-K filings.
$2.2B in FY2025 with a 5-year CAGR of +48.8%. Top quartile in the Health Care sector.
Improved from $1.2B to $2.2B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +59.7%
- 5-Year CAGR
- +48.8%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 155This company $2.2B Sector average $4.5B
▼
-50.8% below sector average
Key checks
Key Insights
- Sarepta Therapeutics's revenue has grown for 3 consecutive years.
- 5-year CAGR of +48.8%, indicating consistent growth.
- In FY2025, revenue increased 15.6% year-over-year.
- Ranks #31 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.2B | +15.6% |
| FY2024 | $1.9B | +53.0% |
| FY2023 | $1.2B | +130.2% |
| FY2022 | $540.1M | -23.1% |
| FY2021 | $701.9M | +133.2% |
| FY2020 | $301.0M | +94.7% |
| FY2019 | $154.6M | -48.6% |
| FY2018 | $301.0M | +94.7% |
| FY2017 | $154.6M | +2751.6% |
| FY2016 | $5.4M | +332.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026